NASDAQ:REGNRegeneron Pharmaceuticals Stock Price, Forecast & News

$612.81

+34.60 (+5.98 %)

(As of 05/29/2020 04:00 PM ET)

Add

Compare

Today's Range

$571.52

Now: $612.81▼

$615.36

50-Day Range

$511.69

MA: $551.03▼

$578.21

52-Week Range

$271.37

Now: $612.81▼

$615.36

Volume6.67 million shs

Average Volume1.38 million shs

Market Capitalization$67.42 billion

P/E Ratio30.79

Dividend YieldN/A

Beta0.53

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it is developing various product candidates for treating patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases, and other diseases. The company has collaboration and license agreements with Sanofi, Bayer, Teva, Mitsubishi Tanabe Pharma, Alnylam Pharmaceuticals, Inc., and others. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.

Beat the Market (BTM) Rank^™

2.3 Analyst's Opinion

Consensus Rating
Regeneron Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.58, and is based on 13 buy ratings, 12 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $538.50, Regeneron Pharmaceuticals has a potential downside of 12.1% from its current price of $612.81.
Amount of Analyst Coverage
Regeneron Pharmaceuticals has been the subject of 16 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.6 Community Rank

Outperform Votes
Regeneron Pharmaceuticals has received 1,343 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Regeneron Pharmaceuticals has received 1,260 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Regeneron Pharmaceuticals has received 51.59% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Regeneron Pharmaceuticals and other stocks. Vote “Outperform” if you believe REGN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe REGN will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Regeneron Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Regeneron Pharmaceuticals does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Regeneron Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $103,732,154.00 in company stock.
Percentage Held by Insiders
Only 11.84% of the stock of Regeneron Pharmaceuticals is held by insiders.
Percentage Held by Institutions
68.02% of the stock of Regeneron Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3 Earnings and Valuation

Earnings Growth
Earnings for Regeneron Pharmaceuticals are expected to grow by 32.38% in the coming year, from $23.84 to $31.56 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Regeneron Pharmaceuticals is 30.79, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 15.35.
Price to Earnings Ratio vs. Sector
The P/E ratio of Regeneron Pharmaceuticals is 30.79, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 26.26.
Price to Earnings Growth Ratio
Regeneron Pharmaceuticals has a PEG Ratio of 1.20. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Regeneron Pharmaceuticals has a P/B Ratio of 5.56. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.43 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryBiotechnology

SectorMedical

Current SymbolNASDAQ:REGN

Previous Symbol

CUSIP75886F10

CIK872589

Webwww.regeneron.com

Phone914-847-7000

Debt

Debt-to-Equity Ratio0.06

Current Ratio4.21

Quick Ratio3.49

Price-To-Earnings

Trailing P/E Ratio30.79

Forward P/E Ratio25.71

P/E Growth1.2

Sales & Book Value

Annual Sales$7.86 billion

Price / Sales8.57

Cash Flow$27.28 per share

Price / Cash Flow22.46

Book Value$110.28 per share

Price / Book5.56

Profitability

EPS (Most Recent Fiscal Year)$21.47

Net Income$2.12 billion

Net Margins28.56%

Return on Equity24.94%

Return on Assets18.81%

Miscellaneous

Employees8,100

Outstanding Shares110,018,000

Market Cap$67.42 billion

Next Earnings Date8/4/2020 (Estimated)

OptionableOptionable

Receive REGN News and Ratings via Email

Sign-up to receive the latest news and ratings for REGN and its competitors with MarketBeat's FREE daily newsletter.

Regeneron Pharmaceuticals (NASDAQ:REGN) Frequently Asked Questions

How has Regeneron Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Regeneron Pharmaceuticals' stock was trading at $464.70 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, REGN shares have increased by 31.9% and is now trading at $612.81. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Regeneron Pharmaceuticals?

26 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 12 hold ratings, 13 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Regeneron Pharmaceuticals.

When is Regeneron Pharmaceuticals' next earnings date?

Regeneron Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Regeneron Pharmaceuticals.

How were Regeneron Pharmaceuticals' earnings last quarter?

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced its quarterly earnings results on Tuesday, May, 5th. The biopharmaceutical company reported $6.60 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $6.13 by $0.47. The biopharmaceutical company had revenue of $1.83 billion for the quarter, compared to the consensus estimate of $1.81 billion. Regeneron Pharmaceuticals had a net margin of 28.56% and a return on equity of 24.94%. The business's revenue for the quarter was up 6.8% on a year-over-year basis. During the same quarter last year, the firm earned $4.45 EPS. View Regeneron Pharmaceuticals' earnings history.

How will Regeneron Pharmaceuticals' stock buyback program work?

Regeneron Pharmaceuticals declared that its board has approved a stock repurchase program on Tuesday, November 5th 2019, which authorizes the company to buyback $1,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to purchase up to 2.9% of its stock through open market purchases. Stock buyback programs are usually an indication that the company's board of directors believes its stock is undervalued.

What price target have analysts set for REGN?

26 analysts have issued 1-year price objectives for Regeneron Pharmaceuticals' stock. Their forecasts range from $325.00 to $734.00. On average, they expect Regeneron Pharmaceuticals' share price to reach $538.50 in the next twelve months. This suggests that the stock has a possible downside of 12.1%. View analysts' price targets for Regeneron Pharmaceuticals.

Has Regeneron Pharmaceuticals been receiving favorable news coverage?

Media stories about REGN stock have trended very negative on Saturday, according to InfoTrie. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Regeneron Pharmaceuticals earned a news sentiment score of -3.5 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 3.0 out of 10, meaning that recent media coverage is unlikely to have an effect on the company's share price in the next several days. View the latest news aboutRegeneron Pharmaceuticals.

Are investors shorting Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 1,870,000 shares, a decline of 7.0% from the April 30th total of 2,010,000 shares. Based on an average trading volume of 1,380,000 shares, the short-interest ratio is currently 1.4 days. Approximately 2.2% of the shares of the stock are short sold. View Regeneron Pharmaceuticals' Current Options Chain.

Who are some of Regeneron Pharmaceuticals' key competitors?

Some companies that are related to Regeneron Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS), Immunomedics (IMMU) and Exelixis (EXEL). View all competitors.

What other stocks do shareholders of Regeneron Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Regeneron Pharmaceuticals investors own include Gilead Sciences (GILD), Netflix (NFLX), NVIDIA (NVDA), Alibaba Group (BABA), Tesla (TSLA), Biogen (BIIB), Micron Technology (MU), Walt Disney (DIS), Alphabet (GOOG) and Johnson & Johnson (JNJ).

Who are Regeneron Pharmaceuticals' key executives?

Regeneron Pharmaceuticals' management team includes the following people:

Dr. Schleifer Leonard S., Co-Founder, Pres, CEO & Exec. Director (Age 66)
Dr. George D. Yancopoulos, Founding Scientist, Pres, Chief Scientific Officer & Director (Age 59)
Mr. Robert E. Landry Jr., Exec. VP of Fin. & CFO (Age 55)
Mr. Daniel P. Van Plew, Exec. VP and GM of Industrial Operations & Product Supply (Age 46)
Ms. Marion E. McCourt, Sr. VP & Head of Commercial (Age 59)

What is Regeneron Pharmaceuticals' stock symbol?

Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."

Who are Regeneron Pharmaceuticals' major shareholders?

Regeneron Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Capital World Investors (6.48%), BlackRock Inc. (6.00%), State Street Corp (3.29%), Loomis Sayles & Co. L P (3.17%), Wellington Management Group LLP (1.87%) and Alliancebernstein L.P. (1.66%). Company insiders that own Regeneron Pharmaceuticals stock include Andrew J Murphy, Arthur F Ryan, Christopher R Fenimore, George L Sing, Joseph J Larosa, Joseph L Goldstein, Leonard S Schleifer, Michael S Brown, Neil Stahl, P Roy Vagelos, Robert E Landry and Sanofi. View institutional ownership trends for Regeneron Pharmaceuticals.

Which institutional investors are selling Regeneron Pharmaceuticals stock?

REGN stock was sold by a variety of institutional investors in the last quarter, including Capital World Investors, Sustainable Growth Advisers LP, Loomis Sayles & Co. L P, Wellington Management Group LLP, Orbimed Advisors LLC, Pictet Asset Management Ltd., Alliancebernstein L.P., and Morgan Stanley. Company insiders that have sold Regeneron Pharmaceuticals company stock in the last year include Andrew J Murphy, Arthur F Ryan, Christopher R Fenimore, George L Sing, Joseph J Larosa, Joseph L Goldstein, Leonard S Schleifer, Michael S Brown, Neil Stahl, P Roy Vagelos, Robert E Landry, and Sanofi. View insider buying and selling activity for Regeneron Pharmaceuticals.

Which institutional investors are buying Regeneron Pharmaceuticals stock?

REGN stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Nuveen Asset Management LLC, Federated Hermes Inc., APG Asset Management N.V., Capital International Investors, Perceptive Advisors LLC, Advisor Group Holdings Inc., and Geode Capital Management LLC. View insider buying and selling activity for Regeneron Pharmaceuticals.

How do I buy shares of Regeneron Pharmaceuticals?

Shares of REGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Regeneron Pharmaceuticals' stock price today?

One share of REGN stock can currently be purchased for approximately $612.81.

How big of a company is Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals has a market capitalization of $67.42 billion and generates $7.86 billion in revenue each year. The biopharmaceutical company earns $2.12 billion in net income (profit) each year or $21.47 on an earnings per share basis. Regeneron Pharmaceuticals employs 8,100 workers across the globe.

What is Regeneron Pharmaceuticals' official website?

The official website for Regeneron Pharmaceuticals is www.regeneron.com.

How can I contact Regeneron Pharmaceuticals?

Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The biopharmaceutical company can be reached via phone at 914-847-7000 or via email at [email protected]

This page was last updated on 5/30/2020 by MarketBeat.com Staff